Spaltudaq

Developer of tumor-specific cancer antibody-based therapeutics Board: Chad Waite $2m Series A seed round at $300k premoney valuation Summary: Developer of tumor-specific cancer antibody-based therapeutics. The company's technology relies upon the patient’s own immune response, yielding not only a specific tumor-binding antibody, but also a validated, disease-associated tumor target. Its platform will enable sampling and recovery of these tumor-specific antibodies with the goal of fulfilling the unmet medical need of novel, safe treatment options for cancer patients.